Skip to main content

About

Aims and scope

The fundamental and interdependent processes responsible for cancer initiation, tumor progression, and the response to treatment pose challenges that call for multidisciplinary efforts. It is increasingly recognized that no single scientific discipline currently possesses the experimental and conceptual tools needed to address all components of this exceedingly complex and heterogeneous disease process. Cancer Convergence creates a single platform to bring together techniques and synergistic perspectives from different disciplines to facilitate the study and development of strategies for curing cancer. This new journal connects researchers from the physical and mathematical sciences and engineering, who bring quantitative approaches, new questions, and testable hypotheses to the study of cancer, with cancer biologists and research oncologists who represent a long tradition of progress toward understanding the emergence and pathogenesis of the disease. As a platform for collaboration, Cancer Convergence welcomes both qualitative and quantitative approaches that offer new insight into the etiology, mechanisms, diagnosis, or treatment of cancer.

Multifaceted physical, chemical, and biological processes maintain homeostasis in animals, and failure of this intricate process often leads to the development of cancer. Therefore, Cancer Convergence welcomes papers from researchers interested in tissue, organ, and systems maintenance where disruption may be a causal agent of cancer. Overall, the journal aims at understanding the principles that operate during normal function of a complex animal body and their relationship to the cancer processes that govern failure at the cellular, tissue, organ, and systems level. While significant advances have been made in cancer research and treatment, a more interdisciplinary approach is needed to achieve a comprehensive understanding of the disease leading to improved diagnostic and treatment strategies.

Benefits of publishing with BMC

High visibility

Cancer Convergence's open access policy allows maximum visibility of articles published in the journal as they are available to a wide, global audience. 

Speed of publication

Cancer Convergence offers a fast publication schedule whilst maintaining rigorous peer review; all articles must be submitted online, and peer review is managed fully electronically (articles are distributed in PDF form, which is automatically generated from the submitted files). Articles will be published with their final citation after acceptance, in both fully browsable web form, and as a formatted PDF.

Flexibility

Online publication in Cancer Convergence gives you the opportunity to publish large datasets, large numbers of color illustrations and moving pictures, to display data in a form that can be read directly by other software packages so as to allow readers to manipulate the data for themselves, and to create all relevant links (for example, to PubMed, to sequence and other databases, and to other articles).

Promotion and press coverage

Articles published in Cancer Convergence are included in article alerts and regular email updates. Some may be highlighted on Cancer Convergence’s pages and on the BMC homepage.

In addition, articles published in Cancer Convergence may be promoted by press releases to the general or scientific press. These activities increase the exposure and number of accesses for articles published in Cancer Convergence. A list of articles recently press-released by journals published by BMC is available here.

Copyright

As an author of an article published in Cancer Convergence you retain the copyright of your article and you are free to reproduce and disseminate your work (for further details, see the BMC license agreement).

For further information about the advantages of publishing in a journal from BMC, please click here.

Open access

All articles published by Cancer Convergence are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers. Further information about open access can be found here.

As authors of articles published in Cancer Convergence you are the copyright holders of your article and have granted to any third party, in advance and in perpetuity, the right to use, reproduce or disseminate your article, according to the BMC license agreement.

For those of you who are US government employees or are prevented from being copyright holders for similar reasons, BMC can accommodate non-standard copyright lines. Please contact us if further information is needed.

Article-processing charges

Open-access publishing is not without costs. Cancer Convergence therefore levies an article-processing charge of £1040.00/$1340.00/€1140.00 for each article accepted for publication, plus VAT or local taxes where applicable. The APC is determined at the date of acceptance.

If the corresponding author's institution participates in our open access membership program, some or all of the publication cost may be covered (more details available on the membership page). We routinely waive charges for authors from low-income countries. For other countries, article-processing charge waivers or discounts are granted on a case-by-case basis to authors with insufficient funds. Authors can request a waiver or discount during the submission process. For further details, see our article-processing charge page.

Visit Springer Nature’s open access funding & support services for information about research funders and institutions that provide funding for APCs.

Springer Nature offers agreements that enable institutions to cover open-access publishing costs. Learn more about our open access agreements to check your eligibility and discover whether this journal is included.

For more information on APCs please see our Journal Pricing FAQs

Indexing services

The full text of all articles is deposited in digital archives around the world to guarantee long-term digital preservation. You can also access all articles published by BMC on SpringerLink. We are working closely with relevant indexing services including PubMed Central and Web of Science (Clarivate Analytics) to ensure that articles published in Cancer Convergence will be available in their databases when appropriate.

Peer-review policy

Peer-review is the system used to assess the quality of a manuscript before it is published. Independent researchers in the relevant research area assess submitted manuscripts for originality, validity and significance to help editors determine whether the manuscript should be published in their journal. You can read more about the peer-review process here.

Cancer Convergence operates a single-blind peer-review system, where the reviewers are aware of the names and affiliations of the authors, but the reviewer reports provided to authors are anonymous.

The benefit of single-blind peer review is that it is the traditional model of peer review that many reviewers are comfortable with, and it facilitates a dispassionate critique of a manuscript.

Submitted manuscripts will generally be reviewed by two to three experts who will be asked to evaluate whether the manuscript is scientifically sound and coherent, whether it duplicates already published work, and whether or not the manuscript is sufficiently clear for publication. The Editors will reach a decision based on these reports and, where necessary, they will consult with members of the Editorial Board.

Citing articles in Cancer Convergence

Articles in Cancer Convergence  should be cited in the same way as articles in a traditional journal. Because articles are not printed, they do not have page numbers; instead, they are given a unique article number.

Article citations follow this format:

Authors: Title. Cancer Converg [year], [volume number]:[article number].

e.g. Roberts LD, Hassall DG, Winegar DA, Haselden JN, Nicholls AW, Griffin JL: Increased hepatic oxidative metabolism distinguishes the action of Peroxisome Proliferator-Activated Receptor delta from Peroxisome Proliferator-Activated Receptor gamma in the Ob/Ob mouse. Cancer Converg 2009, 1:115.

1:115 refers to article 115 from Volume 1 of the journal.

Editorial policies

All manuscripts submitted to Cancer Convergence should adhere to BMC's editorial policies.

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Appeals and complaints

Authors who wish to appeal a rejection or make a complaint should follow the procedure outlined in the BMC Editorial Policies.

Cancer Convergence
Submit manuscript

Follow

On the blog

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here. 

Cancer Convergence

ISSN: 2366-6196

Contact us